Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of unusually large options trading on Tuesday. Traders acquired 140,688 call options on the company. This is an increase of approximately 504% compared to the average daily volume of 23,306 call options.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TEVA. FMR LLC grew its stake in shares of Teva Pharmaceutical Industries by 49.5% during the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Janus Henderson Group PLC boosted its holdings in Teva Pharmaceutical Industries by 7,945.2% during the third quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock worth $86,350,000 after buying an additional 4,732,374 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Teva Pharmaceutical Industries by 237.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after buying an additional 2,376,668 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its position in Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after buying an additional 2,204,623 shares during the period. Finally, State Street Corp increased its holdings in Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after buying an additional 1,778,268 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TEVA shares. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday. UBS Group boosted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $20.88.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $21.20 on Thursday. Teva Pharmaceutical Industries has a 52-week low of $10.13 and a 52-week high of $21.98. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock has a market cap of $24.02 billion, a PE ratio of -24.94, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. The business has a 50-day simple moving average of $17.54 and a 200-day simple moving average of $17.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.